TN2013000325A1 - (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases - Google Patents
(1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterasesInfo
- Publication number
- TN2013000325A1 TN2013000325A1 TNP2013000325A TN2013000325A TN2013000325A1 TN 2013000325 A1 TN2013000325 A1 TN 2013000325A1 TN P2013000325 A TNP2013000325 A TN P2013000325A TN 2013000325 A TN2013000325 A TN 2013000325A TN 2013000325 A1 TN2013000325 A1 TN 2013000325A1
- Authority
- TN
- Tunisia
- Prior art keywords
- triazolo
- inhibitors
- phosphodiesterases
- quinoxaline derivatives
- quinoxaline
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Reproductive Health (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161437848P | 2011-01-31 | 2011-01-31 | |
PCT/EP2012/051546 WO2012104293A1 (fr) | 2011-01-31 | 2012-01-31 | Dérivés de (1,2,4)triazolo[4,3-a]quinoxaline utilisés comme inhibiteurs des phosphodiestérases |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2013000325A1 true TN2013000325A1 (en) | 2015-01-20 |
Family
ID=45833359
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2013000325A TN2013000325A1 (en) | 2011-01-31 | 2013-07-29 | (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases |
Country Status (24)
Country | Link |
---|---|
US (1) | US9540379B2 (fr) |
EP (1) | EP2670754B1 (fr) |
JP (1) | JP6027547B2 (fr) |
KR (1) | KR20140019342A (fr) |
CN (1) | CN103459395A (fr) |
AR (1) | AR085099A1 (fr) |
AU (1) | AU2012213471B2 (fr) |
BR (1) | BR112013019354A2 (fr) |
CA (1) | CA2824929A1 (fr) |
CL (1) | CL2013002003A1 (fr) |
CO (1) | CO6811848A2 (fr) |
EA (1) | EA023792B1 (fr) |
EC (1) | ECSP13012824A (fr) |
GE (1) | GEP20156333B (fr) |
IL (1) | IL226826A (fr) |
MA (1) | MA34844B1 (fr) |
MX (1) | MX2013008667A (fr) |
PE (1) | PE20141023A1 (fr) |
SG (1) | SG192210A1 (fr) |
TN (1) | TN2013000325A1 (fr) |
TW (1) | TWI535718B (fr) |
UA (1) | UA111963C2 (fr) |
UY (1) | UY33888A (fr) |
WO (1) | WO2012104293A1 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA027418B1 (ru) * | 2011-06-27 | 2017-07-31 | Янссен Фармацевтика Нв | ПРОИЗВОДНЫЕ 1-АРИЛ-4-МЕТИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ ИХ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ |
WO2013034755A1 (fr) * | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Dérivés de triazolopyrazine et leur utilisation pour le traitement de troubles neurologiques et psychiatriques |
WO2013034758A1 (fr) * | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Triazolopyrazines substituées et leurs utilisations |
US9056863B2 (en) * | 2011-09-09 | 2015-06-16 | H. Lundbeck A/S | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof |
RU2657540C2 (ru) | 2012-06-26 | 2018-06-14 | Янссен Фармацевтика Нв | Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств |
US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
WO2014139983A1 (fr) | 2013-03-13 | 2014-09-18 | H. Lundbeck A/S | [1,2,4]triazolo[4,3-a]quinoxalines utilisées en tant que doubles inhibiteurs de pde10/pde2 |
WO2015106032A1 (fr) | 2014-01-08 | 2015-07-16 | Intra-Cellular Therapies, Inc. | Produits et compositions pharmaceutiques |
PL3597649T3 (pl) | 2014-04-23 | 2022-04-04 | Dart Neuroscience Llc | Kompozycje zawierające podstawione związki [1,2,4]triazolo[1,5-a]pirymidyn-7-ylowe jako inhibitory pde2 |
EP3215508A1 (fr) | 2014-11-05 | 2017-09-13 | Dart NeuroScience (Cayman) Ltd. | Composés 5-méthyl-[1, 2, 4]-triazolo-[1,5-a)-pyrimidin-2-amines substitués utilisés comme inhibiteurs de pde2 |
MX2017007377A (es) | 2014-12-06 | 2017-11-06 | Intra-Cellular Therapies Inc | Compuestos organicos. |
WO2016090380A1 (fr) | 2014-12-06 | 2016-06-09 | Intra-Cellular Therapies, Inc. | Composés organiques |
EP3156405A1 (fr) | 2015-10-13 | 2017-04-19 | Boehringer Ingelheim International GmbH | Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide |
EP3440071A1 (fr) | 2016-03-21 | 2019-02-13 | Perlara PBC | Composés organiques hérérocycliques fusionnés et leurs utilisations |
CN106212487B (zh) * | 2016-07-28 | 2018-11-13 | 浙江工业大学 | 一种含甲氧基苯并吡嗪结构的1,2,4-三唑衍生物作为杀菌剂的应用 |
CA3083176A1 (fr) | 2017-11-23 | 2019-05-31 | Oslo University Hospital Hf | Traitement de la tachycardie |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5153196A (en) | 1991-06-05 | 1992-10-06 | Eli Lilly And Company | Excitatory amino acid receptor antagonists and methods for the use thereof |
US6235740B1 (en) * | 1997-08-25 | 2001-05-22 | Bristol-Myers Squibb Co. | Imidazoquinoxaline protein tyrosine kinase inhibitors |
DE10108752A1 (de) | 2001-02-23 | 2002-09-05 | Bayer Ag | Neue Substituierte Imidazotriazinone |
JP2006521343A (ja) * | 2003-03-27 | 2006-09-21 | ファイザー・プロダクツ・インク | 置換4−アミノ[1,2,4]トリアゾロ[4,3−a]キノキサリン |
WO2004096220A1 (fr) * | 2003-04-30 | 2004-11-11 | Merck Frosst Canada Ltd. | 8-(3-biaryl)phenylquinoleines comme inhibiteurs de la phosphodiesterase de type 4 |
WO2005041957A1 (fr) | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Derives d'oxindole et leur utilisation comme inhibiteurs de la phosphodiesterase de type 2 |
WO2005061497A1 (fr) | 2003-12-16 | 2005-07-07 | Pfizer Products Inc. | Pyrido[2,3-d]pyrimidine-2,4-diamines en tant qu'inhibiteurs de la pde 2 |
EP1548011A1 (fr) | 2003-12-23 | 2005-06-29 | Neuro3D | Dérivés de 1,4-benzodiazépine-2-one comme inhibiteurs de PDE2 phosphodiesterase, leurs préparation et utilisation thérapeutique |
FR2870539B1 (fr) | 2004-05-19 | 2006-08-04 | Greenpharma Sa Sa | Nouvelles methodes et medicaments |
BRPI0514586A (pt) | 2004-09-02 | 2008-06-17 | Altana Pharma Ag | triazolftalazinas |
AU2006204451C1 (en) | 2005-01-05 | 2012-05-24 | Takeda Gmbh | Triazolophthalazines as PDE2-inhibitors |
KR20070095986A (ko) | 2005-01-05 | 2007-10-01 | 니코메드 게엠베하 | Pde2 억제제로서의 트리아졸로프탈라진 |
BRPI0502411A (pt) | 2005-03-31 | 2006-11-28 | Univ Minas Gerais | processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados |
CA2636043A1 (fr) | 2006-01-23 | 2007-08-02 | Amira Pharmaceuticals, Inc. | Inhibiteurs tricycliques de la 5-lipoxygenase |
WO2007121319A2 (fr) | 2006-04-14 | 2007-10-25 | University Of California | Compostions et procédés destinés à déterminer et à prevoir des réponses aux traitements de la dépression et de l'anxiété |
TW200815436A (en) | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
TW200817400A (en) | 2006-05-30 | 2008-04-16 | Elbion Ag | Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
DE102006048693A1 (de) | 2006-10-14 | 2008-04-17 | Bayer Healthcare Ag | Inhibition der PDE2A |
KR101563103B1 (ko) | 2006-12-13 | 2015-10-23 | 아스카 세이야쿠 가부시키가이샤 | 퀴녹살린 유도체 |
CN101918408A (zh) | 2007-11-30 | 2010-12-15 | 惠氏有限责任公司 | 作为磷酸二酯酶10的抑制剂的芳基和杂芳基稠合的咪唑并[1,5-a]吡嗪 |
WO2009086303A2 (fr) | 2007-12-21 | 2009-07-09 | University Of Rochester | Procédé permettant de modifier la durée de vie d'organismes eucaryotes |
TWI501965B (zh) | 2008-06-20 | 2015-10-01 | Lundbeck & Co As H | 作為pde10a酵素抑制劑之新穎苯基咪唑衍生物 |
KR20110095857A (ko) | 2008-09-10 | 2011-08-25 | 칼립시스, 인코포레이티드 | 질환의 치료를 위한 히스타민 수용체의 헤테로시클릭 억제제 |
WO2010054253A1 (fr) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Dérivés de triazine en tant qu’inhibiteurs de phosphodiestérases |
WO2010104933A1 (fr) | 2009-03-11 | 2010-09-16 | Merck Sharp & Dohme Corp. | Inhibiteurs de l'activité akt |
TW201111383A (en) * | 2009-05-29 | 2011-04-01 | Wyeth Llc | Substituted imidazo[1,5-a]quinoxalines as inhibitors of phosphodiesterase 10 |
EP2266985A1 (fr) | 2009-06-26 | 2010-12-29 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Dérivés de pyrimidine tricycliques en tant qu'antagonistes Wnt |
WO2012096929A2 (fr) | 2011-01-11 | 2012-07-19 | Sunovion Pharmaceuticals Inc. | Composés hétéroaryles et leurs procédés d'utilisation |
EA027418B1 (ru) | 2011-06-27 | 2017-07-31 | Янссен Фармацевтика Нв | ПРОИЗВОДНЫЕ 1-АРИЛ-4-МЕТИЛ[1,2,4]ТРИАЗОЛО[4,3-a]ХИНОКСАЛИНА, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ИХ ОСНОВЕ, СПОСОБЫ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ ИХ, ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ |
US9056863B2 (en) | 2011-09-09 | 2015-06-16 | H. Lundbeck A/S | Substituted 2,3,5,9,9B-pentaazacyclopenta[a]naphthalenes and uses thereof |
WO2013034758A1 (fr) | 2011-09-09 | 2013-03-14 | H. Lundbeck A/S | Triazolopyrazines substituées et leurs utilisations |
RU2657540C2 (ru) | 2012-06-26 | 2018-06-14 | Янссен Фармацевтика Нв | Комбинации, содержащие ингибиторы pde 2, такие как 1-арил-4-метил-[1,2,4]триазоло[4,3-а]хиноксалиновые соединения, и ингибиторы pde 10, для применения в лечении неврологических или метаболических расстройств |
US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
-
2012
- 2012-01-30 US US13/361,002 patent/US9540379B2/en active Active
- 2012-01-31 MX MX2013008667A patent/MX2013008667A/es active IP Right Grant
- 2012-01-31 EA EA201300871A patent/EA023792B1/ru not_active IP Right Cessation
- 2012-01-31 CA CA2824929A patent/CA2824929A1/fr not_active Abandoned
- 2012-01-31 UA UAA201310356A patent/UA111963C2/uk unknown
- 2012-01-31 WO PCT/EP2012/051546 patent/WO2012104293A1/fr active Application Filing
- 2012-01-31 EP EP12708774.0A patent/EP2670754B1/fr active Active
- 2012-01-31 GE GEAP201213211A patent/GEP20156333B/en unknown
- 2012-01-31 CN CN2012800157168A patent/CN103459395A/zh active Pending
- 2012-01-31 JP JP2013550908A patent/JP6027547B2/ja active Active
- 2012-01-31 KR KR1020137023101A patent/KR20140019342A/ko not_active Application Discontinuation
- 2012-01-31 AR ARP120100303A patent/AR085099A1/es unknown
- 2012-01-31 PE PE2013001585A patent/PE20141023A1/es not_active Application Discontinuation
- 2012-01-31 TW TW101103150A patent/TWI535718B/zh not_active IP Right Cessation
- 2012-01-31 MA MA36142A patent/MA34844B1/fr unknown
- 2012-01-31 UY UY0001033888A patent/UY33888A/es not_active Application Discontinuation
- 2012-01-31 AU AU2012213471A patent/AU2012213471B2/en not_active Ceased
- 2012-01-31 BR BR112013019354A patent/BR112013019354A2/pt not_active IP Right Cessation
- 2012-01-31 SG SG2013057815A patent/SG192210A1/en unknown
-
2013
- 2013-06-09 IL IL226826A patent/IL226826A/en not_active IP Right Cessation
- 2013-07-08 CL CL2013002003A patent/CL2013002003A1/es unknown
- 2013-07-29 TN TNP2013000325A patent/TN2013000325A1/fr unknown
- 2013-07-29 CO CO13179130A patent/CO6811848A2/es not_active Application Discontinuation
- 2013-08-13 EC EC2013012824A patent/ECSP13012824A/es unknown
Also Published As
Publication number | Publication date |
---|---|
CN103459395A (zh) | 2013-12-18 |
EA023792B1 (ru) | 2016-07-29 |
US20120302564A1 (en) | 2012-11-29 |
ECSP13012824A (es) | 2013-10-31 |
GEP20156333B (en) | 2015-07-27 |
CA2824929A1 (fr) | 2012-08-09 |
EP2670754B1 (fr) | 2017-05-24 |
WO2012104293A1 (fr) | 2012-08-09 |
NZ611630A (en) | 2015-03-27 |
KR20140019342A (ko) | 2014-02-14 |
IL226826A (en) | 2016-10-31 |
UY33888A (es) | 2012-08-31 |
SG192210A1 (en) | 2013-09-30 |
PE20141023A1 (es) | 2014-09-04 |
AU2012213471B2 (en) | 2016-07-14 |
BR112013019354A2 (pt) | 2019-09-24 |
CO6811848A2 (es) | 2013-12-16 |
CL2013002003A1 (es) | 2013-12-06 |
TW201245198A (en) | 2012-11-16 |
US9540379B2 (en) | 2017-01-10 |
EA201300871A1 (ru) | 2014-01-30 |
EP2670754A1 (fr) | 2013-12-11 |
MX2013008667A (es) | 2013-10-01 |
AU2012213471A1 (en) | 2013-07-04 |
JP6027547B2 (ja) | 2016-11-16 |
TWI535718B (zh) | 2016-06-01 |
MA34844B1 (fr) | 2014-01-02 |
AR085099A1 (es) | 2013-09-11 |
JP2014503576A (ja) | 2014-02-13 |
UA111963C2 (uk) | 2016-07-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2013000325A1 (en) | (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases | |
AU2018236800B2 (en) | DNA-PK inhibitors | |
IN2014DN07384A (fr) | ||
MX347917B (es) | Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso. | |
NZ700928A (en) | Dna-pk inhibitors | |
UA107952C2 (uk) | ПОХІДНІ ІМІДАЗО[1,2-a]ПІРАЗИНУ І ЇХ ЗАСТОСУВАННЯ ДЛЯ ПРОФІЛАКТИКИ АБО ЛІКУВАННЯ НЕВРОЛОГІЧНИХ, ПСИХІАТРИЧНИХ І МЕТАБОЛІЧНИХ РОЗЛАДІВ І ЗАХВОРЮВАНЬ | |
LT3418281T (lt) | Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui | |
MX370814B (es) | Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas. | |
TN2014000255A1 (en) | Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors | |
MX2011012353A (es) | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus. | |
MX357502B (es) | Derivados de pirrolotriazinona. | |
PH12014501829A1 (en) | Bicyclic pyrazinone derivatives | |
PH12015501586A1 (en) | 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors | |
MX2014008864A (es) | Derivados de triazolo[4,5-d]pirimidina. | |
EA201290744A1 (ru) | Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов | |
MX336332B (es) | Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia. | |
MX2014011326A (es) | Derivados de 6-(4-(1-amino-3-hidroxiciclobutil) fenil)-5-fenil (furo, tieno o pirrolo) [2, 3-d] pirimidin 4-ona para el tratamiento de cancer. | |
MX362197B (es) | Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos. | |
UA111520C2 (uk) | [1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази | |
MX2014006015A (es) | Derivados de 3-fenil-isoquinolin-1 (2h) -ona como inhibidores de parp-1. | |
TN2013000377A1 (en) | Thieno [2, 3-d] pyrimidine derivatives and their use to treat arrhythmia | |
AP3582A (en) | (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases | |
NZ621597A (en) | Triazolopyridine compounds as pde10a inhibitors |